MLTX INVESTOR ALERT: RGRD LLP Announces that MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Core Viewpoint - The MoonLake class action lawsuit alleges that MoonLake Immunotherapeutics and its executives violated the Securities Exchange Act of 1934, impacting investors who purchased or acquired its common stock [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases, with its primary drug candidate being sonelokimab (SLK) for treating hidradenitis suppurativa (HS) [3]. Allegations - The lawsuit claims that MoonLake made false or misleading statements regarding SLK's efficacy compared to Union Chimique Belge's BIMZELX, which is an FDA-approved monoclonal antibody for HS [4]. - Specific allegations include that SLK and BIMZELX target the same inflammatory cytokines (IL-17A and IL-17F), and that SLK's unique Nanobody structure does not provide superior clinical benefits or increased tissue penetration as claimed [4]. Stock Impact - Following the announcement of disappointing Phase 3 VELA program results on September 28, 2025, which indicated SLK's failure to demonstrate competitive efficacy against BIMZELX, MoonLake's stock price plummeted nearly 90% [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased MoonLake common stock during the class period to seek lead plaintiff status in the lawsuit, representing the interests of the class [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone, and is recognized for securing significant monetary relief for investors [7].